Chimerix presents promising clinical data for CMX001 in late-breaker poster session at 50th ICAAC

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today presented promising clinical data for CMX001 in a late-breaker poster session at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).  

Wendy Painter, M.D., Chief Medical Officer of Chimerix, presented pharmacokinetic and preliminary safety data pertaining to renal function from 46 patients enrolled in Investigator-held Emergency Investigational New Drug applications (EINDs).  The majority of patients participating in the EIND program had received stem cell or bone marrow transplant procedures, and presented with severe renal impairment attributed to prior administration of the antiviral drug Vistide® (cidofovir).  Data from the EIND patient case studies demonstrate that following the administration of CMX001, renal function improved or remained unchanged in the majority of patients.  Further, moderate-to-severe renal impairment in both pediatric and adult patients, did not alter systemic exposure to CMX001.  CMX001 exposure was also not affected by hemodialysis.

"CMX001 was well tolerated in patients with severe viral infections with no evidence of nephrotoxicity, which has been a significant dose-limiting factor for several existing therapies," stated Dr. Painter.  "The data also show that the pharmacokinetics of CMX001 are unchanged in patients with renal impairment, a major complication for severely ill patients.  We are gratified by the growing body of evidence supporting CMX001's broad-spectrum antiviral activity and excellent tolerability profile."

To date, Chimerix has treated nearly 100 patients under investigator-held EINDs or foreign equivalent at leading medical centers in the US, Canada and Europe for the treatment of a wide-range of life-threatening infections caused by double-stranded DNA viruses for which there are either no FDA-approved treatments or where patients have failed the available treatment.

These data were presented at the 50th ICAAC during the late-breaker "Pharmacokinetics and Pharmacodynamics of HIV and Antiviral Agents" session at 9:30 am ET in a presentation titled "Compromised Renal Function Does Not Affect the Pharmacokinetics of CMX001 in Patients with Severe Double-Stranded DNA Virus Infections" (Abstract #A1-2017a). Hosted by the American Society for Microbiology (ASM), the 50th ICAAC provides physicians, researchers, and other medical professionals from around the world an opportunity to deliberate on global solutions for infectious disease.  

SOURCE Chimerix, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Blocking nidogen-2 enhances chemotherapy efficacy in pancreatic cancer